News

Hosted on MSN29d
FDA to review Regeneron’s sBLA for aflibercept injection 8mg
The US Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ supplemental biologics licence application (sBLA) for Eylea HD (aflibercept) injection 8mg for priority review.
Seeking Alpha28d
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application
“Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation EYLEA HD ® (aflibercept) Injection 8 mg; uncertainty of the ...
Nasdaq29d
Regeneron's SLBA For EYLEA HD Injection 8 Mg Gets Acceptance From FDA For Priority Review
(RTTNews) - Regeneron Pharmaceuticals ... the supplemental Biologics License Application for EYLEA HD (aflibercept) Injection 8 mg for the treatment of retinal vein occlusion.
Yahoo Finance28d
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application
TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals ... for EYLEA HD ® (aflibercept) Injection 8 mg across all approved indications. The CRL did not identify any ...